Findlay D M, Houssami S, Christopoulos G, Sexton P M
St. Vincent's Institute of Medical Research, Fitzroy, Australia.
Endocrinology. 1996 Nov;137(11):4576-85. doi: 10.1210/endo.137.11.8895320.
UMR106-06 cells predominantly express the C1a isoform of the rat calcitonin (CT) receptor (CTR). We have compared the homologous regulation of the C1a CTR endogenously expressed in UMR106-06 cells with the cloned C1a CTR in transfected HEK 293 cells, in which expression is driven by a heterologous promoter. It was found that treatment of both cell lines with either salmon CT or human CT reduced the density of cell surface CTR in a dose- and time-dependent manner. However, the magnitude of the response was greater in UMR106-06 cells, and salmon CT was more potent than human CT in both cell lines. Recovery from down-regulation was rapid in transfected cells (< 2 h), but was comparatively delayed in UMR106-06 cells, where less than 70% of receptor-binding capacity had returned by 24 h. In both cell lines, treatment with either agonist increased the basal activity of CT-sensitive adenylate cyclase and caused a time-dependent reduction in the responsiveness of adenylate cyclase to a second challenge with CT. Reduced responsiveness occurred under conditions of minimal loss of CTR from the cell surface, consistent with an uncoupling of the receptor from the signal transduction apparatus. Recovery of CT-sensitive adenylate cyclase was complete in transfected cells by 24 h, but was delayed in UMR106-06 cells, paralleling the slow recovery of receptor binding. CT-induced down-regulation of the CTR was not mimicked by receptor-independent activation of protein kinase A or protein kinase C. However, treatment of cells for 24 h, but not for 4 h, with phorbol ester caused a partial loss of CTR binding in UMR106-06 cells and resulted in an approximately 200% increase in CTR binding in transfected HEK 293 cells. CTR messenger RNA levels, as assessed by reverse transcription-PCR, were not changed by any of the above treatments. These results suggest that CT-induced receptor down-regulation and modulation of the ability of CT to activate adenylate cyclase are inherent properties of the receptor, as they can be recapitulated in an otherwise CTR-naive cell line, in which receptor expression is driven by a heterologous gene promoter. Moreover, and in contrast with CTR regulation in osteoclasts, activation of protein kinase A is insufficient for ligand-induced regulation of the CTR in these nonosteoclastic cell lines, and receptor regulation does not appear to involve altered messenger RNA levels.
UMR106 - 06细胞主要表达大鼠降钙素(CT)受体(CTR)的C1a亚型。我们比较了UMR106 - 06细胞中内源性表达的C1a CTR与转染的HEK 293细胞中克隆的C1a CTR的同源调节情况,在转染的HEK 293细胞中,其表达由异源启动子驱动。结果发现,用鲑鱼降钙素或人降钙素处理这两种细胞系,均以剂量和时间依赖性方式降低细胞表面CTR的密度。然而,UMR106 - 06细胞中的反应幅度更大,并且在两种细胞系中鲑鱼降钙素比人降钙素更有效。转染细胞中下调后的恢复很快(<2小时),但在UMR106 - 06细胞中相对延迟,在24小时时受体结合能力恢复不到70%。在两种细胞系中,用任何一种激动剂处理均可增加CT敏感的腺苷酸环化酶的基础活性,并导致腺苷酸环化酶对CT再次刺激的反应性随时间下降。在细胞表面CTR损失最小的情况下发生反应性降低,这与受体与信号转导装置的解偶联一致。转染细胞中CT敏感的腺苷酸环化酶在24小时时完全恢复,但在UMR106 - 06细胞中延迟恢复,这与受体结合的缓慢恢复相似。CT诱导的CTR下调不能被蛋白激酶A或蛋白激酶C的非受体依赖性激活所模拟。然而,用佛波酯处理细胞24小时而非4小时,会导致UMR106 - 06细胞中CTR结合部分丧失,并导致转染的HEK 293细胞中CTR结合增加约200%。通过逆转录 - PCR评估,上述任何处理均未改变CTR信使RNA水平。这些结果表明,CT诱导的受体下调和CT激活腺苷酸环化酶能力的调节是受体的固有特性,因为它们可以在另一种原本不表达CTR的细胞系中重现,在该细胞系中受体表达由异源基因启动子驱动。此外,与破骨细胞中的CTR调节相反,蛋白激酶A的激活不足以在这些非破骨细胞系中诱导配体介导的CTR调节,并且受体调节似乎不涉及信使RNA水平的改变。